AstraZeneca PLC (AZN) Announced Positive Results for its Phase 3 Trial of Gefurulimab

AstraZeneca PLC (NASDAQ:AZN) is one of the Stocks With Huge Catalysts on the Horizon. On July 24, AstraZeneca PLC (NASDAQ:AZN) announced positive results for its global Phase 3 trial of Gefurulimab in adults with generalized myasthenia gravis who are antibody-positive.

Management noted that the trial was randomized, double-blind, and placebo-controlled. It met its primary and all secondary endpoints as patients showed significant improvement in their daily activities related to gMG at 26 weeks compared to placebo. gMG is a rare autoimmune disease that causes muscle weakness and loss of function. CEO of AstraZeneca PLC Rare Disease Marc Dunoyer noted that the results confirm gefurulimab’s potential as a fast-acting and sustained treatment option. Management expects the treatment to become first-line with a good safety profile.

AstraZeneca PLC (AZN) Announced Positive Results for its Phase 3 Trial of Gefurulimab

A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases.

AstraZeneca PLC is a biopharmaceutical company that focuses on oncology, rare diseases, cardiovascular, respiratory, immunology, and vaccines.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.